Search the Newsreel

Oncology Institute (NASDAQ: TOI) awards 30,120 RSUs to director

Oncology Institute director Mark L. Pacala was granted 30,120 restricted stock units (RSUs), increasing his direct holdings to 286,881 shares. These RSUs will vest in full at the company's 2027 annual meeting of stockholders, contingent upon his continued service. This transaction was reported in …

Kura Oncology (NASDAQ: KURA) revises CEO and executive severance

Kura Oncology (NASDAQ: KURA) has revised the employment agreements for its CEO, CCO, and COO to update severance and change-of-control protections. These new terms define cash severance, COBRA coverage, equity vesting, and stock option exercise rights, differentiating based on whether a termination is linked …

CGON (CGON) insider files to sell 4,303 shares after option exercise

An insider at CG Oncology, Inc. (CGON) has filed a Form 144 notice to sell 4,303 common shares after exercising stock options on July 29, 2026. This sale will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services. The filing also details …

Asahi Songwon Colors Ltd. Revenue Breakdown – NSE:ASAHISONG

ALX Oncology Holdings Inc (ALXO) Financial Health: Profitability & Balance Sheet Analysis

The article analyzes the financial health of ALX Oncology Holdings Inc (ALXO), noting its weak financial status and low operating efficiency with a score of 5.40 out of 385 in the Biotechnology & Medical Research industry. It highlights that relevant financial data for Quality …

Colony Bankcorp (CBAN) Holds Steady Near Resistance Amid Light Trading - Opening Range Breakout

BridgeBio Oncology Therapeutics Inc. (BBOT) Q1 2026 Earnings: Narrower-Than-Expected Loss but Shares Slide Amid Pre-Revenue Status - Banking Earnings Report

Oncology Institute Inc (TOI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Oncology Institute Inc (TOI), noting its current valuation score of 7.50, ranking 52 out of 75 in its industry. The company's current P/E ratio is -13.88, which is significantly below its recent high and above its recent …

Liquidity Mapping Around (CGEM) Price Events

This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting weak near and mid-term sentiment but a strong long-term outlook. It identifies key support and resistance levels, offering three AI-generated trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. …

CGON (CGON) insider Ambaw Bellete files to sell 50,000 shares

Ambaw Bellete, an insider at CG Oncology, Inc. (CGON), has filed a Form 144 indicating an intention to sell 50,000 shares of common stock. This planned sale, valued at approximately $3.6 million, is scheduled for on or after July 28, 2026, and is connected …

LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $108

LifeSci Capital has reiterated its Buy rating on CG Oncology (CGON.US) and maintained its target price of $108. This indicates continued confidence from the firm in the company's prospects.

ALX Oncology Holdings Inc. $ALXO Stock Position Boosted by venBio Partners LLC

venBio Partners LLC significantly increased its stake in ALX Oncology Holdings Inc. ($ALXO) by 32.8% in Q1, acquiring over 3.18 million additional shares. This makes ALXO the third-largest holding in venBio's portfolio, representing 9.58% of ALXO's total shares. Despite the company missing its latest …

Is Aktis Oncology (AKTS) Fairly Valued After Its Recent Pullback?

Aktis Oncology (AKTS) stock has experienced a recent pullback, dropping 4% in the past week and 17% in the last month, despite year-to-date gains. The company, which focuses on radiopharmaceutical research, trades at a Price-to-Book (P/B) ratio of 2.6x, slightly above the US Biotech …

A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $28 to $40

This article provides a quick look at analyst ratings for Kura Oncology (KURA.US). Forecasts for the company's stock price range from $28 to $40. Investors are encouraged to consider these ratings as part of a broader investment strategy.

KURA Reiterates by Wedbush -- Price Target Maintained at $36

Wedbush has reiterated an "Outperform" rating for Kura Oncology (KURA) and maintained a price target of $36.00, signaling confidence despite the company's low GF Score™ of 28/100, which highlights profitability and growth challenges. Insider activity, marked by $1.0 million in net selling and no …

Kura Oncology Reports 50% Response Rate in RCC Combination Study

Kura Oncology announced promising updated results from its Phase 1 FIT-001 trial, showing a 50% objective response rate in cabozantinib-naive clear cell RCC patients treated with darlifarnib and cabozantinib. The combination therapy demonstrated a manageable safety profile, with neutropenia being the most notable adverse …

For AML patients with limited options, Cullinan plans a new study

Cullinan Therapeutics received positive feedback from the FDA for its FLT3xCD3 T cell engager CLN-049 in acute myeloid leukemia (AML), paving the way for a potentially registrational Phase 2 study in Q3 2026. The study will focus on relapsed/refractory AML, an area with limited …

Why is Cullinan Therapeutics stock climbing today?

Cullinan Therapeutics (CGEM) stock rose in pre-open trading after receiving positive FDA feedback for CLN-049, a drug for relapsed/refractory acute myeloid leukemia. The company plans to initiate a potentially registrational Phase 2 study in Q3 2026, which investors view as an accelerated path to …

Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.

Champions Oncology, Inc. provided a tranche update on its equity buyback plan announced on April 5, 2023. From February 1, 2026, to April 30, 2026, the company did not repurchase any shares. However, since the plan's inception, the company has completed the repurchase of …

BridgeBio Oncology Therapeutics, Inc. Revenue Breakdown – NASDAQ:BBOT

The article focuses on BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) and its revenue breakdown, accessible through TradingView's financial section. It provides an overview of market data, fundamentals, and statistics for the company. The content appears to be a stub or a navigation page within …

ALX Oncology Holdings Inc (ALXO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for ALX Oncology Holdings Inc (ALXO), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It displays current stock information including the market cap and P/E TTM. …

CTOR Q2 2026 Earnings: Significant EPS Miss Highlights Ongoing Development Stage - Non-GAAP Earnings

CG Oncology Inc. (CGON) Experiences Modest Pullback as Shares Trade Near Support - Cash Secured Put

Champions Oncology Inc. (CSBR) Slides 8.75% as Selling Pressure Intensifies - NHNL Ratio

Cardiff Oncology (NASDAQ:CRDF) Shares Up 1.1% - Should You Buy?

Insider Buying: Oncology Institute (NASDAQ:TOI) Major Shareholder Buys 18,000 Shares

Cardiff Oncology (CRDF) Expected to Post Quarterly Earnings on Tuesday

The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Call

The Oncology Institute, Inc. (TOI) announced that it will release its second quarter 2026 financial results on Thursday, August 6, 2026. This will be followed by a conference call at 5:00 p.m. (Eastern Time) on the same day. Interested parties can access the call …

Colonial Sfl Socimi SA (WBO:COL) Q2 2026 Earnings Call Highlights: Strong Rental Income Growth ...

This article first appeared on GuruFocus. Gross Rental Income: 207 million, up 5% year-on-year. Recurring Earnings: 111 million, 4% growth year-on-year. EPRA EPS: 0.178, up 4% year-on-year. Occupancy Rate: Increased by 200 basis points to 94%. Net Tangible Assets: 6.0 billion, with a per …

Colonial Motor Co Ltd Revenue Breakdown – NZX:CMO

CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

DALLAS, July 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced the publication of results from the pivotal Phase 3 BOND-003 Cohort C trial evaluating cretostimogene grenadenorepvec monotherapy in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with …

About 81% of BOND-003 patients maintained their bladders at 24 months

CG Oncology (NASDAQ: CGON) announced the publication of pivotal Phase 3 BOND-003 Cohort C study results in The Lancet Oncology. The study evaluated cretostimogene grenadenorepvec monotherapy for high-risk, BCG-unresponsive non-muscle invasive bladder cancer and met its primary endpoint with a 75.5% complete response rate. …

Champions Oncology outlines fiscal 2027 plan with Corellia fully funded as it reports $59.4M revenue and $1.6M adjusted EBITDA

Earnings Call Insights: Champions Oncology (CSBR) Q4 fiscal 2026 MANAGEMENT VIEW * CEO Robert Brainin said the company delivered “record annual revenue” and “met our commitment to full year positive adjusted EBITDA,” including “positive adjusted EBITDA in each of the 4 quarters on its …

CHAMPIONS ONCOLOGY, INC. FY 2026: Revenue $59.43M, EPS ($0.08) — 10-K Summary

Champions Oncology, Inc. reported fiscal year 2026 revenue of $59.43 million, a 4.4% increase from the prior year, driven by higher pharmacology services and conversion of delayed studies. Despite revenue growth, the company experienced a net loss of ($1.18M) and diluted EPS of ($0.08), …

Champions Oncology Reports Record Annual Revenue of $59 Million

Champions Oncology, Inc. announced record annual revenue of $59.4 million for fiscal year 2026, alongside its fourth consecutive quarter of positive Adjusted EBITDA. The company highlighted significant progress in strategic priorities, including expanding its radiopharmaceutical platform and strengthening its data strategy, which it believes …

BlackRock, Inc. (CGON) discloses 6.8% beneficial ownership in CG Oncology

BlackRock, Inc. has filed an amended Schedule 13G disclosing a 6.8% beneficial ownership in CG Oncology (CGON), amounting to 6,023,696 shares of common stock. BlackRock holds sole voting power over 5,914,671 shares and sole dispositive power over all 6,023,696 shares. The filing specifies that …